Jane Street’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Jane Street’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-514	Closed	-$3.09K	–	9997
2023 Q3	$3.09K	Sell	514 -548	-52%	-$3.86K	﹤0.01%	8470
2023 Q2	$7.33K	Buy	+1,062	New	+$7K	﹤0.01%	8467
2022 Q1	–	Sell	-653	Closed	-$30K	–	11259
2021 Q4	$30K	Sell	653 -24	-4%	-$1.61K	﹤0.01%	9698
2021 Q3	$57K	Sell	677 -229	-25%	-$18.9K	﹤0.01%	9509
2021 Q2	$86K	Sell	906 -243	-21%	-$28.8K	﹤0.01%	9330
2021 Q1	$191K	Buy	+1,149	New	+$152K	﹤0.01%	8306
2019 Q1	–	Sell	-82	Closed	-$9K	–	5807
2018 Q4	$9K	Buy	+82	New	+$16.4K	﹤0.01%	4829
2014 Q3	–	Sell	-8	Closed	-$15K	–	3188
2014 Q2	$15K	Buy	+8	New	+$15.8K	﹤0.01%	2484

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PPW

Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Jane Street's ONCT Position: Q4 2023 in Review

Jane Street sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 514 shares — an estimated $3.09K sold.

Jane Street first reported a position in ONCT in Q2 2014 and held it in 8 quarters. The position peaked at $191K in Q1 2021. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

Jane Street reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Jane Street sold 514 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.09K.
Jane Street first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2014 and held it in 8 quarters.
Jane Street's Oncternal Therapeutics, Inc. Common Stock position peaked at $191K in Q1 2021.
38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Jane Street's 13F filing for Q4 2023, filed 15 Feb 2024.